Solaris Asset Management LLC Has $165,000 Stake in Bristol-Myers Squibb Co. (BMY)

Solaris Asset Management LLC raised its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 3.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 2,244 shares of the biopharmaceutical company’s stock after buying an additional 75 shares during the period. Solaris Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $165,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Stillwater Investment Management LLC boosted its position in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Stillwater Investment Management LLC now owns 3,467 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 16 shares during the period. Shayne & CO. LLC raised its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Shayne & CO. LLC now owns 3,946 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 18 shares in the last quarter. Founders Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Founders Capital Management LLC now owns 4,022 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 19 shares in the last quarter. 1832 Asset Management L.P. raised its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. 1832 Asset Management L.P. now owns 3,066 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 22 shares in the last quarter. Finally, Cribstone Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 1.7% in the second quarter. Cribstone Capital Management LLC now owns 4,081 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 67 shares in the last quarter. 72.87% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.86% on Monday, reaching $49.34. 11,577,968 shares of the company’s stock were exchanged. Bristol-Myers Squibb Co. has a 52-week low of $49.10 and a 52-week high of $77.12. The company has a market cap of $82.44 billion, a PE ratio of 28.85 and a beta of 0.75. The firm’s 50 day moving average price is $54.82 and its 200 day moving average price is $66.24.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The company earned $4.90 billion during the quarter, compared to analysts’ expectations of $4.60 billion. During the same period last year, the company posted $0.53 EPS. Bristol-Myers Squibb’s revenue was up 17.2% on a year-over-year basis. On average, analysts expect that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a yield of 3.08%. Bristol-Myers Squibb’s dividend payout ratio is currently 87.36%.

A number of brokerages have weighed in on BMY. Jefferies Group raised their target price on shares of Bristol-Myers Squibb from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, July 14th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Wednesday, July 13th. Berenberg Bank restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 12th. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 target price on the stock in a research report on Monday, July 25th. Finally, SunTrust Banks Inc. lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $86.00 to $68.00 in a research report on Friday, August 5th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $69.06.

In other news, Director Lamberto Andreotti sold 23,200 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $59.17, for a total value of $1,372,744.00. Following the completion of the sale, the director now directly owns 364,999 shares in the company, valued at $21,596,990.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.